Investors Warned of Class Action Against ImmunityBio, Inc. Amid Securities Fraud Allegations

Investor Alert: Class Action Lawsuit Filed Against ImmunityBio, Inc.

Pomerantz LLP, a prestigious law firm known for its dedication to protecting the rights of investors, has announced that a class action lawsuit has been initiated against ImmunityBio, Inc., listed on NASDAQ under the ticker IBRX. This lawsuit targets ImmunityBio and its officers for alleged securities fraud and other unlawful business practices, prompting affected investors to act promptly.

According to Pomerantz, investors who suffered losses on their ImmunityBio investments should reach out to Danielle Peyton at the law firm for support. Those interested in potentially becoming the Lead Plaintiff in this case must contact the firm by May 26, 2026. The firm has urged investors to provide their contact information and the number of shares they purchased to facilitate the process.

The lawsuit's backdrop began with alarming news about ImmunityBio's bladder cancer drug, Anktiva. On March 24, 2026, the U.S. Food and Drug Administration (FDA) publicly released a warning letter dated March 13, indicating that despite previous admonitions, ImmunityBio continued to promote Anktiva in misleading ways. This included advertisements featured on television and Sean Spicer's podcast, revealing a disturbing pattern of disregard for regulatory standards.

As a direct consequence of the FDA's disclosure, ImmunityBio's stock plummeted by $1.99 per share, a staggering drop of 21.12%, closing at $7.41 on March 24, 2026. This significant decline reflects investor anxiety regarding the company's practices and its repercussions on shareholder assets.

Pomerantz LLP has a storied history, having been at the forefront of corporate, securities, and antitrust litigation for85 years. The firm, founded by the late Abraham L. Pomerantz, has consistently advocated for victims of securities fraud, earning numerous multimillion-dollar settlements on behalf of its class members. This law firm is well-prepared to take on ImmunityBio as part of its ongoing commitment to justice and accountability in the corporate world.

If you believe your rights have been violated as a shareholder of ImmunityBio, it is crucial to consider participation in this class action. Gaining clarity on your legal standing can be instrumental in recovering your losses. For more information on joining the class action, investors are encouraged to visit Pomerantz Law Firm's website.

In these uncertain times, navigating the complexities of corporate governance and investor protections can be daunting. However, firms like Pomerantz LLP exist to fight for the integrity of financial markets and the rights of investors everywhere. As this litigation advances, many eyes will be on the path it carves for future securities fraud actions, aiming for greater transparency and accountability among publicly traded companies.